Unilever Drops $1.2B on Grüns as Supplement M&A Heats Up
Supplement industry deals Q2 2026 reveal wellness is now a core growth strategy, not a side bet, for global food and health companies.
Unilever just paid $1.2 billion for Grüns. That number tells operators everything they need to know about where the supplement industry deals of Q2 2026 are pointing.
TLDR
- Unilever’s $1.2B Grüns acquisition signals wellness is now core strategy.
- Gut health, protein, and longevity categories drove the heaviest deal flow.
- Personalized nutrition platforms attracted capital as customer retention tools.
- Retailers and food companies are acquiring science, not just brands.
- Scale and durable consumer relationships defined Q2 dealmaker priorities.
Supplement Industry Deals Q2 2026: Scale Meets Science
Unilever’s $1.2 billion acquisition of Grüns set the tone early. NutraIngredients-USA reports the quarter saw dealmakers chase three things simultaneously: scale, science, and stickier customer relationships.
That combination is new. For years, wellness acquisitions chased brand equity alone.
Now acquirers want the data layer too. Personalized nutrition platforms drew significant capital precisely because they generate longitudinal health data. That data reduces churn and justifies premium pricing.
Function’s acquisition of Suppco is one clear example. The deal connects supplement recommendations directly to individual health data, per NutraIngredients reporting. Operators watching subscription attrition rates should note the model.
Gut Health, Protein, and Longevity Lead the Category Race
Gut health attracted multiple deals this quarter. Next-generation approaches, including bacteriophage-based interventions, are moving from research pipelines into commercial acquisition targets. Significant.
Protein remained a high-volume category for deal activity. Longevity-focused brands also drew acquirer interest, reflecting demographic tailwinds that show no sign of reversing.
Euglena’s acquisition of Kobelco Eco-Solutions’ microalgae business adds a supply-side dimension. The full Q2 deal roundup underscores how ingredient infrastructure is becoming as strategically valuable as finished brands.
For manufacturers and retailers, the quarter’s activity maps a clear competitive pressure. Companies that control both the science and the consumer relationship will compress margin space for those that control neither. The clean-label and transparency movement accelerating alongside this M&A wave is not coincidental. Acquirers are paying premiums for brands consumers already trust. That trust is the asset.
Source: NutraIngredients-USA. https://www.nutraingredients.com/Article/2026/06/30/supplement-industry-deals-of-q2-2026/